Econ One economists and statisticians have extensive experience with pharmaceutical and healthcare markets. Combining economic expertise with in-depth industry knowledge, Econ One has provided economic and statistical analysis in a broad range of antitrust, contract dispute, false claims, and reimbursement matters. We have a comprehensive understanding of publicly available and confidential datasets such as health insurance claims from Medicare, Medicaid, and commercial payors; usual and customary benchmarks for provider bill charges; and transactional data maintained by pharmaceutical manufacturers regarding sales and net pricing. This understanding, along with our economic and statistical expertise enables us to leverage this data to make defensible assessments of issues such as damages, relevant market industry characteristics, and other topics.
Econ One has extensive experience working with counsel for direct purchasers of various pharmaceuticals on generic delay cases such as pay-for-delay and product hopping, and in antitrust disputes over alleged monopolization in contract pricing and reimbursement for the provision of health care services. In these cases, we use econometric and economic analysis to assess whether common evidence can be used to determine impact and damages on a class-wide basis. Our analyses in these cases focus on defining relevant markets, assessing market power, determining the competitive effects of the allegedly anticompetitive behavior, and calculating overcharges.
Econ One experts bring a rich foundation in statistics to our work, such as sampling in False Claims Act cases, benchmarking usual and customary rates for out-of-network provider billed charges, and empirical analysis of prescription drug reimbursement based on average wholesale prices.